IP Library Granted Patent US 11,559,429
Granted Patent B1
US 11,559,429 · App. 17/952,218 · Granted Jan 24, 2023

Punctal plug and bioadhesives

Inventors: Noah Silverberg (Santa Barbara, CA); Mark Silverberg (Santa Barbara, CA)
Assignee: OCULAR THERAPEUTIX, INC.
A61F9/00772A61L31/04A61L31/148A61K9/0048A61L2430/16
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,559,429
App. No.
17/952,218
Filed
Sep 24, 2022
Granted
Jan 24, 2023
Kind
B1
Examiner
TRAN, NHU
Art Unit
3781
USPC
604/294
Abstract

The present disclosure provides devices and methods for the treatment of ophthalmological conditions such as dry eye. Among the devices provided are punctal plugs and devices for inserting punctal plugs. The punctal plugs may be shaped for insertion in the punctum and/or the canaliculus. They may also be coated with a bioadhesive. Methods for inserting the punctal plugs are provided, as well as methods for preparing bioadhesive-coated punctal plugs. A method is also provided to treat dry-eye using a bioadhesive without use of a punctal plug.

Claims (4)

1. A method of treating an ophthalmological condition comprising:

(i) inserting a temporary lacrimal insert comprising a punctal plug portion and an intracanalicular portion into a punctum of an eye; wherein the punctal plug portion is configured to keep the intracanalicular portion from migrating into the lacrimal sac and wherein the intracanalicular portion is configured to prevent the punctal plug portion from extruding from the punctum; wherein the intracanalicular portion molds to a shape of a canaliculus; wherein the lacrimal insert comprises a biodegradable polymer; and wherein the time required for the lacrimal insert to adhere to tissue in the punctum sufficiently to stabilize the lacrimal insert in place is about 15 seconds to about 5 minutes; wherein the biodegradable polymer is not collagen or synthetic collagen; wherein the biodegradable polymer is selected from polyethylene glycol; polyethylenes; polyglycolides; polyhydroxyalkanoates; or any combination thereof; and wherein the lacrimal insert further comprises polyethylene glycol based hydrogel sealant disposed on a body surface oriented to contact the tissue of the punctum of a subject; and

(ii) occluding the punctum with the inserted lacrimal insert;

wherein the ophthalmological condition is dry eye.

Assignments (1)
SECURITY INTEREST Recorded Aug 2, 2023
From: OCULAR THERAPEUTIX, INC.
To: BARINGS FINANCE LLC, AS AGENT
Reel/Frame 064476/0368 →
Continuity (2)
Continuation 15766647
Provisional Application 62239006 · Oct 8, 2015
Cited By (3)
US 12,310,890 US 12,678,400 US 12,678,401